Table 1 A summary of HLA associations, epitopes, and antigens available through literature and public databases
From: Immunopeptidomics for autoimmunity: unlocking the chamber of immune secrets
HLA Allele(s) | Protective HLA allele? | Number of epitopes | Number of antigens | Experimental setting | PTM identification | Reference |
|---|---|---|---|---|---|---|
Rheumatoid Arthritis | ||||||
 DRB1 alleles | No | 103 | 888 | Immunopeptidomics | CITR, HYL | Maggi, J. et al.159 |
 DRB1*04 (*04:01, *04:04, *04:05, and *04:08) | No | 98 | 22 | In vitro assays | CITR, HYL, GLYC | IEDB |
 DRB1*10:01 | No | 11 | 5 | In vitro assays | CITR | IEDB |
 DRB1*09:01 | No | None reported on IEDB |  |  |  |  |
 DRB1*01:03 | Yes | None reported on IEDB |  |  |  |  |
 DRB1*13 (*13:01, 13:02) | Yes | None reported on IEDB |  |  |  |  |
 DRB1*04:02 | Yes | None reported on IEDB |  |  |  |  |
 DRB1*04:02/11:04, *01:01/04:01, 01:01/04:01, 04:01/15:01, 08:01/15:01 | No | 1593 | 870 | Immunopeptidomics | CITR | Wang, Q. et al.153 |
 DRB1*04:03, DRB1*08:03, DRB3*02:02, and DRB5*01:01 | No | N/A(compiled datasets) | N/A(compiled datasets) | Immunopeptidomics | Not reported | Kaabinejadian, S. et al.156 |
 Not specified | N/A | 1260 | 334 | Proteomics | GLYC | Xu, Z. et al.160 |
Type 1 Diabetes | ||||||
 A*02, A*03 |  | 58 | 34 | Immunopeptidomics | TRANSPEP | Azoury, M. E. et al.161 |
 A*02 |  | 254 | 164 | Immunopeptidomics | TRANSPEP | Gonzalez-Duque, S. et al.116 |
 HLA A*24:02 |  | 46 | 27 |  |  | Dolton, G. et al.162 |
 HLA-A*02:01 |  | 32 | 2 |  |  | Anderson, A. M. et al.163 |
 B7 |  | 11 | 3 | In vitro assays |  | Unger, W. W. et al.164 |
 B*08:01 |  | 21 | 4 | In vitro assays |  | Toma, A. et al.165 |
 HLA-C*03:04 |  | 4 | 1 | In vitro assays |  | Anderson, A. M. et al.163 |
 DP |  | 3 | 2 | In vitro assays |  | Landry, L. G. et al.166 |
 DQ8 |  | 65 | 7 | In vitro assays | DEAM | van Lummel, M. et al.167 |
 DQ8 |  | 10 | 3 | Immunopeptidomics | HIPs | Tran, M. T. et al.168 |
 DRB1*04:01 |  | 45 | 16 | Proteomics | CITR/DEAM | Callebaut, A. et al.169 |
 DRB1*04:01 |  | 80 | 17 | In vitro assays | HIPs | Arribas-Layton, D. et al.170 |
Systemic Lupus Erythematosus | ||||||
 A2 |  | 1 | 1 | In vitro assays | None | Berner, B. R. et al.171 |
 DP |  | 1 | 1 | In vitro assays | None | Ito, H. et al.172 |
 DR15 |  | 148 | 4 | In vitro assays | None | Eggenhuizen, P. J. et al.173 |
 DRB1 |  | 5 | 1 | In vitro assays | None | Greidinger, E. L. et al.174 |
 Not specified |  | 7 | 1 | In vitro assays | None | Ito, H. et al.172 |
 DR |  | 81 | 10 | In vitro assays | None | Lu, L. et al.175 |
Lyme Arthritis | ||||||
 DRB1*01:03/03:01, 04:03/15:01, 04:01,03:01 | Not known | 30 | 23 | Immunopeptidomics | None | Kanjana, K. et al.176 |
 DRB1*04:02/11:04, 01:01/04:01, 01:01/08:01, 10:01/11:01 | Not known | 1427 | 166 | Immunopeptidomics | None | Seward, R. J. et al.152 |
Multiple Sclerosis | ||||||
 DR15 | No | 2567 | 1241 | Immunopeptidomics | None | Wang, J. et al.28 |
 DR16 | No | 170 | 57 | Proteomics | None | Mohme, M. et al.177 |
 DRA*01:01 | No | 26 | 8 | Proteomics | None | Lee, M. N. & Meyerson, M.178 |
 DP | N/A | 16 | 1 | Proteomics | None | Joshi, N. et al.179 |
 A*02:01 | No | 106 | 11 | Proteomics | None | Lolli, F. et al.180 |
 A/B/C and DR | N/A | 237 | 170 | Immunopeptidomics | None | Fissolo, N. et al.181 |
Ankylosing Spondylitis | ||||||
 B*27 | No | 38 | 12 | Yeast display | None | Yang, X. et al.182 |
 B*27:05 and B*27:09 | No | 3 | 1 | In vitro assays | CITR | Beltrami, A. et al.183 |
Psoriasis | ||||||
 C*06:02 |  | 1 | 1 | In vitro assays | None | Arakawa A. et al.184 |
 DRB1*04, DRB1*07 |  | 13 | 1 | In vitro assays | None | Shen, Z. et al.185 |
 Various |  | 1 | 1 | In vitro assays | None | Lande R et al.186 |
Systemic sclerosis / Scleroderma | ||||||
 DRB1:11*04, DRB1:07:01, DRB1*15:01 |  | 11 | 1 | In vitro assays | None | Tiniakou, E. et al.187 |
DPB1*13:01, DQA1*02:01, DQA1*05:01, DRB1*07:01, DPA1*02:01, DQB1*03:01, DRB1*15:01, B*08:01, A*24, A*30, A*32 | No | None reported | None reported | N/A | N/A | Â |
 DRB1*08:01, DQB*02:02, B*44:03 | Yes | None reported | None reported | N/A | N/A |  |
Celiac Disease | ||||||
 DQ2/DQ8 |  | 339 | 30 | In vitro assays | DEAM, ACET | IEDB |
 DQ2.5, DQ2.2, and DQ7.5 |  | 12,712 | Not reported | Immunopeptidomics | DEAM | Bergseng, E. et al.188 |
